tiprankstipranks
Trending News
More News >
Osteopore Ltd. (AU:OSX)
ASX:OSX
Australian Market
Advertisement

Osteopore Ltd. (OSX) AI Stock Analysis

Compare
9 Followers

Top Page

AU:OSX

Osteopore Ltd.

(Sydney:OSX)

Rating:39Underperform
Price Target:
AU$0.00
▼(-100.00% Downside)
Osteopore Ltd.'s overall stock score is primarily influenced by weak financial performance and technical indicators. The company's struggle with profitability and cash flow management, combined with bearish technical signs and valuation challenges, present significant risks. The absence of earnings call data and corporate events further limits insights into future prospects.

Osteopore Ltd. (OSX) vs. iShares MSCI Australia ETF (EWA)

Osteopore Ltd. Business Overview & Revenue Model

Company DescriptionOsteopore Limited designs, develops, and markets bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery applications in Singapore, Australia, and internationally. Its technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. The company offers Osteoplug, a bioresorbable implant, which is used for covering trephination burr holes in neurosurgery; and Osteomesh, a bioresorbable implant that is used in craniofacial surgery to repair various types of fractures, such as orbital floor fracture, as well as to fill surgical defects. Osteopore Limited has a collaboration agreement with Livingstone Health Holding Limited to jointly develop new applications and products for regenerating bone and tissue. The company was incorporated in 2003 and is headquartered in Singapore.
How the Company Makes MoneyOsteopore Ltd. generates revenue through the sale of its bioresorbable implants to hospitals, clinics, and medical practitioners. The company leverages its proprietary 3D printing technology to produce custom implants tailored to specific patient needs, which can command premium pricing. Additionally, Osteopore may engage in partnerships with healthcare organizations and distributors to expand its market reach and enhance sales. The company could also explore licensing agreements for its technology, further diversifying its revenue streams.

Osteopore Ltd. Financial Statement Overview

Summary
Osteopore Ltd. shows revenue growth but struggles with profitability and cash flow. High debt and ongoing losses increase financial risk, despite strong gross margins.
Income Statement
40
Negative
Osteopore Ltd. shows consistent revenue growth, with a 26.82% increase in 2024. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins over the years. The gross profit margin remained healthy at over 84% in 2024, but the persistent negative EBIT and net income indicate significant operational challenges and high costs relative to revenue.
Balance Sheet
45
Neutral
The balance sheet reveals a high debt-to-equity ratio, with total debt surpassing equity in 2024, increasing financial risk. The equity ratio decreased significantly, indicating a shift towards higher leverage. ROE is negative due to ongoing losses, raising concerns over shareholder returns. However, the company maintains some cash reserves, which may provide short-term liquidity.
Cash Flow
38
Negative
Osteopore Ltd. faces cash flow challenges, with negative operating and free cash flows throughout the periods. The free cash flow growth rate is negative, highlighting ongoing cash burn. The operating cash flow to net income ratio remains unfavorable, reflecting inefficiencies in converting revenue into cash. The firm is reliant on financing activities to sustain operations, which could pose risks if funding sources become limited.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.81M2.22M1.78M1.40M2.23M
Gross Profit2.37M1.64M1.36M1.10M1.68M
EBITDA-2.34M-4.35M-3.97M-3.38M-1.76M
Net Income-3.35M-4.87M-4.22M-3.93M-2.69M
Balance Sheet
Total Assets3.13M3.34M3.62M6.01M10.25M
Cash, Cash Equivalents and Short-Term Investments638.50K1.16M2.16M5.13M9.03M
Total Debt1.33M1.09M74.18K106.71K453.99K
Total Liabilities2.83M2.91M1.51M633.40K1.25M
Stockholders Equity306.22K432.60K2.11M5.37M9.00M
Cash Flow
Free Cash Flow-3.10M-3.74M-4.06M-4.00M-2.14M
Operating Cash Flow-3.11M-3.74M-4.00M-3.81M-1.76M
Investing Cash Flow-14.59K-7.37K-63.98K-194.62K-381.04K
Financing Cash Flow2.63M3.58M842.24K-485.88K7.84M

Osteopore Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.02
Negative
200DMA
0.03
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
46.70
Neutral
STOCH
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OSX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.70 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:OSX.

Osteopore Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
AU$213.92M-4.06%20.36%64.81%
51
Neutral
$7.38B-0.04-62.85%2.34%15.18%-2.87%
51
Neutral
AU$298.66M-29.77%6.07%59.09%
50
Neutral
AU$26.29M-74.80%-9.16%89.23%
47
Neutral
AU$16.63M-17.24%34.47%41.83%
40
Underperform
AU$118.95M-85.35%315.11%51.16%
39
Underperform
AU$2.61M-907.51%24.60%65.60%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:OSX
Osteopore Ltd.
0.01
-0.03
-75.00%
AU:OCC
Orthocell Ltd
1.22
0.84
221.05%
AU:ARX
Aroa Biosurgery Ltd
0.62
0.02
3.33%
AU:IME
ImExHS Limited
0.26
-0.22
-45.83%
AU:EMD
Emyria Ltd
0.05
0.01
25.00%
AU:ALA
Arovella Therapeutics Limited
0.10
-0.04
-28.57%

Osteopore Ltd. Corporate Events

Osteopore Secures Key Tender Wins in Vietnam’s Growing Orthopaedic Market
Aug 4, 2025

Osteopore Ltd. has successfully won tender bids to supply its orthopaedic products to two major public hospitals in Vietnam, marking a significant entry into the Vietnamese market. This development is expected to enhance Osteopore’s market position in the Asia Pacific region, particularly in the high-growth high tibial osteotomy and bone grafting markets, which are projected to grow significantly. The company plans to work with its distribution partner to finalize logistics and supply arrangements, aiming to capitalize on the growing demand driven by Vietnam’s aging population and increasing prevalence of orthopaedic conditions.

Osteopore Ltd. Announces Quotation of New Securities on ASX
Jul 31, 2025

Osteopore Ltd. has announced the quotation of 30,120,481 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 31, 2025. This move is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operational capabilities and offering new opportunities for stakeholders.

Osteopore Achieves Record Revenue and EU MDR Clearance
Jul 31, 2025

Osteopore Limited has reported a record quarterly revenue of AUD 835K for Q2 CY25, marking a 15% increase quarter-on-quarter and an 11% rise year-on-year. The company has also secured EU MDR clearance for its custom orthopaedic and cranial implants, which is expected to open new revenue streams and enhance its market presence in the European Union.

Osteopore Reports Triple Growth in Sales Through Zimmer Biomet Partnership
Jul 29, 2025

Osteopore Limited has reported significant progress following its Exclusive Distribution Agreement with Zimmer Biomet, a global medical technology leader. Over the first 12 months of the partnership, sales of Osteopore’s craniofacial products in Europe, Australia, and Hong Kong have tripled compared to the previous year. This growth highlights the company’s resilience in manufacturing and its ability to scale operations effectively. With recent European approval for custom-made cranioplasty implants, Osteopore anticipates increased market traction and plans to expand into new markets in collaboration with Zimmer Biomet.

Osteopore Ltd. Announces Change in Substantial Shareholding
Jul 23, 2025

Osteopore Ltd. has announced a change in the substantial holding of its shares, with Advance Opportunities Fund I reducing its stake from 11.63% to 9.07%. This shift in voting power reflects a sale of shares amounting to A$66,965.31, which may impact the company’s market dynamics and investor relations.

Advance Opportunities Fund Ceases Substantial Holding in Osteopore
Jul 22, 2025

Osteopore Limited has announced that the Advance Opportunities Fund has ceased to be a substantial holder in the company. This change involves the indirect sale of shares valued at A$20,201.75, affecting 1,432,748 voting securities. The announcement may impact the company’s shareholder structure and market perception.

Osteopore Secures Clearance for Jawbone Regeneration Study
Jul 20, 2025

Osteopore Ltd. has received Research Governance Office clearance for a clinical study at Princess Alexandra Hospital, focusing on jawbone regeneration using its advanced PCL-TCP scaffold technology. This study aims to address the challenges of current treatments by exploring a regenerative approach that could improve patient outcomes globally, with the first patient recruitment expected in four weeks.

Osteopore Ltd. Sees Shift in Substantial Holder’s Voting Power
Jul 18, 2025

Osteopore Ltd. has announced a significant change in the interests of a substantial holder, Advance Opportunities Fund, which has reduced its voting power in the company. This change involves the indirect sale of shares in the market, affecting the fund’s voting power from 9.96% to 5.55%. This adjustment in shareholding may impact the company’s market dynamics and influence its strategic decisions.

Osteopore Initiates Groundbreaking Pediatric Study for Temporal Hollowing
Jul 16, 2025

Osteopore Ltd. has announced the recruitment of its first patient in a clinical study at Queensland Children’s Hospital, aiming to treat temporal hollowing in children following cranial vault remodelling surgery. The study will explore the use of a 3D-printed, patient-specific scaffold combined with bone marrow aspirate and platelet-rich fibrin to restore the frontotemporal contour. This initiative underscores Osteopore’s commitment to advancing regenerative medicine solutions, particularly for pediatric patients, and positions the company as a leader in innovative medical technology.

Advance Opportunities Fund I Becomes Substantial Holder in Osteopore Ltd.
Jul 15, 2025

Osteopore Ltd. has announced that Advance Opportunities Fund I has become a substantial holder in the company, acquiring a significant number of fully paid ordinary shares. This acquisition, amounting to 24,096,385 shares and representing an 11.63% voting power, was completed with a consideration of A$200,000. The involvement of Advance Opportunities Fund I as a substantial holder could potentially impact Osteopore’s market position and shareholder dynamics, reflecting increased investor interest and confidence in the company’s prospects.

Osteopore Ltd. Announces Quotation of New Securities on ASX
Jul 14, 2025

Osteopore Ltd. has announced the quotation of 24,096,385 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 14, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially strengthening its position in the medical technology sector and offering new opportunities for stakeholders.

Osteopore Secures Swiss Market Approval for Innovative Implants
Jul 13, 2025

Osteopore Limited has secured market approval in Switzerland for its 3D-printed biomimetic and bioresorbable implants under the EU Medical Device Regulation. This approval, following a successful transition to the MDR and a partnership with Zimmer Biomet, enables Osteopore to strengthen its market presence in Switzerland and across Europe, providing a complete suite of craniofacial products. The approval is expected to enhance Osteopore’s operations and industry positioning, particularly in the European cranial implant market, which is projected to grow significantly.

Osteopore Ltd. Announces Change in Substantial Holding
Jul 7, 2025

Osteopore Ltd. has announced a change in substantial holding, with the Advance Opportunities Fund I ceasing to be a substantial holder. This change involves indirect selling in the market, impacting 1,600,000 voting securities with a consideration of A$17,600.00. The announcement reflects a shift in the company’s shareholder structure, which could influence its market dynamics and stakeholder relationships.

Osteopore Ltd. Sees Change in Substantial Shareholding
Jun 30, 2025

Osteopore Ltd. has announced a change in the substantial holding of its shares by the Advance Opportunities Fund I. The fund has reduced its voting power from 7.15% to 6.02% through a series of market transactions. This change in shareholding could impact the company’s market dynamics and investor relations as it reflects a shift in stakeholder interest.

Osteopore Ltd. Sees Change in Substantial Shareholder Interests
Jun 24, 2025

Osteopore Ltd. has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, which has reduced its voting power from 8.25% to 7.15% by selling 2,000,000 shares. This adjustment in shareholding could impact the company’s market dynamics and stakeholder interests, reflecting a shift in investment strategy by a significant shareholder.

Advance Opportunities Fund I Becomes Substantial Holder in Osteopore Ltd.
Jun 23, 2025

Osteopore Ltd. has announced that Advance Opportunities Fund I has become a substantial holder in the company, acquiring a significant voting power with fully paid ordinary shares. This development indicates a strategic investment move, potentially impacting the company’s market positioning and shareholder dynamics.

Osteopore Ltd. Announces Issuance of New Securities
Jun 19, 2025

Osteopore Ltd. has announced the issuance of 9,615,384 fully paid ordinary securities to be quoted on the ASX, effective June 19, 2025. This move is part of the company’s strategy to enhance its capital structure and support its growth initiatives, potentially strengthening its market position and providing value to its stakeholders.

Advance Opportunities Fund I Ceases Substantial Holding in Osteopore Ltd.
Jun 13, 2025

Osteopore Ltd. has announced that Advance Opportunities Fund I has ceased to be a substantial holder in the company. This change in substantial holding reflects a shift in the voting securities, with the fund selling a significant number of shares, potentially impacting the company’s market dynamics and stakeholder interests.

Osteopore Ltd. Sees Change in Substantial Shareholder Interests
Jun 6, 2025

Osteopore Ltd. has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, in its voting securities. The fund has reduced its stake in Osteopore Ltd. from 6.74% to 5.52% by selling shares in the market, which may impact the company’s shareholder structure and influence in decision-making processes.

Osteopore Ltd. Announces Change in Substantial Shareholding
Jun 5, 2025

Osteopore Ltd. has reported a change in the substantial holding of its shares by Advance Opportunities Fund I. The fund’s voting power has decreased from 7.89% to 6.74%, indicating a reduction in its stake in the company. This change could impact the company’s shareholder dynamics and influence in decision-making processes.

Osteopore Initiates Clinical Trial for Jawbone Reconstruction
Jun 3, 2025

Osteopore Limited has announced a new clinical trial in collaboration with Princess Alexandra Hospital to explore maxillomandibular reconstruction using their polycaprolactone-tricalcium phosphate scaffolds. This trial aims to assess the safety and tolerability of the technique, which could potentially offer a more adaptable and less invasive alternative to current treatments. The trial’s success could enhance Osteopore’s industry positioning and lead to further market approvals, benefiting stakeholders by potentially improving patient outcomes and expanding the company’s clinical applications.

Osteopore Ltd. Announces Director Departure and Securities Update
May 30, 2025

Osteopore Ltd. announced the cessation of Daniel Ow as a director effective May 29, 2025. The notice details his relevant interests in securities, including multiple tranches of performance rights expiring in 2030. This change in directorship could impact the company’s strategic direction and stakeholder confidence, given the significant role directors play in guiding company operations.

Osteopore Limited Successfully Passes All Resolutions at AGM
May 30, 2025

Osteopore Limited, a company listed on the Australian Securities Exchange, held its Annual General Meeting on May 30, 2025. During the meeting, all proposed resolutions were passed, including a special resolution for a 10% placement facility, indicating strong shareholder support and potentially enhancing the company’s financial flexibility.

Osteopore Ltd. Announces Issuance of Convertible Notes
May 23, 2025

Osteopore Ltd. has announced the issuance of convertible notes, marking a strategic financial move to potentially enhance its capital structure. This issuance may impact the company’s operational capabilities and market positioning by providing additional resources for growth and development, potentially benefiting stakeholders through increased innovation and market reach.

Osteopore Ltd. Secures Further Investment Through Convertible Notes
May 23, 2025

Osteopore Ltd. has issued a Cleansing Notice related to its agreement with Advance Opportunities Fund for the issuance of convertible notes. This notice allows the company to issue shares upon conversion of these notes without further disclosure, facilitating retail investment. The agreement involves a subscription amount of up to $20 million, with the latest tranche amounting to $500,000. This strategic financial move is expected to enhance Osteopore’s operational capabilities and market positioning by securing necessary funding for its ongoing projects.

Osteopore Advances with Additional Funding for Growth
May 23, 2025

Osteopore Limited has announced a further drawdown of Tranche 1 of their redeemable convertible notes, with subscribers investing an additional A$500,000 in two equal sub-tranches. The funds raised will be used for the company’s ordinary business activities and potential future developments, projects, and investments. This strategic financial move supports Osteopore’s ongoing operations and growth in the regenerative medicine industry, potentially enhancing its market position and offering opportunities for stakeholders.

Osteopore and Queensland Children’s Hospital Launch Clinical Trial for Temporal Hollowing
May 22, 2025

Osteopore Limited, in collaboration with Queensland Children’s Hospital, has initiated a clinical trial to treat temporal hollowing in children post-cranial vault remodelling surgery for craniosynostosis. This trial, which employs a 3D-printed, patient-specific polycaprolactone-tricalcium phosphate onlay scaffold, aims to assess its feasibility in restoring frontotemporal contour, potentially offering a less invasive alternative to current methods. The study has received ethical clearance and is supported by Maddox’s Helping Hand Foundation, highlighting its potential impact on improving surgical outcomes for young patients.

Osteopore Ltd. Advances Capital Raising with Convertible Notes Issuance
May 16, 2025

Osteopore Ltd. has issued a Cleansing Notice regarding the issuance of Third Convertible Notes, part of a subscription agreement with Advance Opportunities Fund. This agreement involves a subsequent investment of $500,000, allowing the company to issue shares without further disclosure to retail investors. The issuance of these convertible notes is expected to impact the company’s financial position and market operations, enhancing its ability to raise capital and expand its market presence.

Osteopore Advances Funding with Additional Convertible Notes Subscription
May 16, 2025

Osteopore Limited has announced a further drawdown of Tranche 1 of its redeemable convertible notes, with subscribers committing to an additional A$500,000, bringing the total to A$3,500,000 out of a possible A$5,000,000 for this tranche. The funds raised will be used for the company’s ordinary business operations and future development projects, potentially enhancing Osteopore’s market positioning in the regenerative medicine industry.

Osteopore Ltd. Announces Director’s Interest Change
May 12, 2025

Osteopore Ltd. has announced a change in the director’s interest, specifically involving Mark Leong. The notice details the various classes of securities and options held by the director, both directly and indirectly, as of May 7, 2025. This change in director’s interest is a routine disclosure that may impact the company’s governance and transparency, providing stakeholders with updated information on the director’s financial interests in the company.

Osteopore Limited Sees Increase in Substantial Holder’s Voting Power
May 9, 2025

Osteopore Limited has announced a change in the interests of a substantial holder, Advance Opportunities Fund I, in its voting securities. The fund’s voting power has increased from 5.62% to 7.89%, reflecting a significant shift in shareholder dynamics, which could impact the company’s strategic decisions and influence within the industry.

Osteopore Ltd. Expands Capital with New ASX Quotation
May 9, 2025

Osteopore Ltd. has announced the quotation of 7,812,500 new ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from May 8, 2025. This move is expected to enhance the company’s capital base, potentially strengthening its market position and providing additional resources to support its operations and growth initiatives.

Osteopore Ltd. to Quote 2 Million Shares on ASX
May 9, 2025

Osteopore Ltd. announced the issuance of 2,000,000 fully paid ordinary shares under an employee incentive scheme, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s ongoing efforts to incentivize and retain talent, potentially strengthening its operational capabilities and market position in the medical technology sector.

Osteopore Ltd. Announces Board Changes and Consultancy Role for Departing Director
May 8, 2025

Osteopore Limited has announced that Non-Executive Director Daniel Ow will step down from the Board, effective 29 May 2025, citing personal reasons. Despite his departure, the company plans to retain Mr. Ow’s expertise by appointing him as a financial consultant, allowing Osteopore to continue benefiting from his valuable financial insights. This move is expected to maintain stability and continuity in the company’s operations and strategic direction.

Osteopore Ltd. Issues 11.6 Million Performance Rights
May 8, 2025

Osteopore Ltd. has announced the issuance of 11,625,000 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions until the end of the restriction period. This move is likely aimed at aligning employee interests with company performance, potentially enhancing motivation and retention within the workforce.

Osteopore Ltd. Announces Quotation of New Securities on ASX
May 8, 2025

Osteopore Ltd. has announced the application for quotation of 526,754 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, which may enhance employee engagement and align their interests with company growth, potentially impacting the company’s market positioning positively.

Advance Opportunities Fund Acquires Substantial Stake in Osteopore Ltd.
May 7, 2025

Osteopore Ltd. has announced that the Advance Opportunities Fund has become a substantial holder of its fully paid ordinary shares. The fund acquired a significant number of shares, which amounts to a 9.96% voting power in the company. This development indicates a strong vote of confidence in Osteopore’s operations and could potentially enhance its market position by attracting more investor interest.

Osteopore Ltd. Sees Reduction in Substantial Shareholding by Advance Opportunities Fund I
May 7, 2025

Osteopore Ltd. has experienced a change in the substantial holding of its shares, with Advance Opportunities Fund I reducing its stake from 8.24% to 5.62%. This transaction involved the sale of 4,000,000 shares for A$66,000. The reduction in voting power could impact the company’s shareholder dynamics and influence, potentially affecting decision-making processes and strategic directions.

Osteopore Ltd. Announces Quotation of New Securities on ASX
May 6, 2025

Osteopore Ltd. has announced the quotation of 10,869,565 fully paid ordinary shares on the Australian Securities Exchange (ASX) as of May 6, 2025. This move is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operations and stakeholder interests positively by increasing its capital base.

Osteopore Introduces Employee Securities Incentive Plan
May 6, 2025

Osteopore Limited has announced the implementation of an Employee Securities Incentive Plan. This plan aims to offer securities to eligible employees, enhancing their engagement and aligning their interests with the company’s growth objectives. The initiative is expected to strengthen employee commitment and potentially improve the company’s operational performance.

Osteopore Expands Craniofacial Implant Distribution in Thailand
May 6, 2025

Osteopore Limited has entered into an exclusive two-year distribution agreement with Peakmed Co., Ltd, a Thailand-based medical device company, to distribute its craniofacial implants across 70 hospitals in Thailand. This strategic partnership aims to strengthen Osteopore’s market presence in Thailand, a key market due to the high volume of neurosurgical procedures, and aligns with the company’s strategy to expand its distribution channels in the growing Southeast Asian healthcare market.

Osteopore Ltd. Sees Shift in Substantial Shareholder Interests
May 5, 2025

Osteopore Ltd. has experienced a change in the interests of a substantial holder, Advance Opportunities Fund I, which has adjusted its voting power from 9.75% to 8.24% through a series of transactions involving fully paid ordinary shares. This shift in shareholding could impact the company’s market dynamics and influence its strategic decisions, reflecting a potential change in investor confidence or strategy.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 31, 2025